newsfilter
← Latest News
GlobeNewswire·

Selecta Biosciences and Sobi Announce Completion of Enrollment in DISSOLVE Phase 3 Study Evaluating SEL-212 for Chronic Refractory Gout

-DISSOLVE program on track with 12-month study fully enrolled--DISSOLVE II on track for full enrollment in early 2022--Top-line data from Phase 3 DISSOLVE program expected in H2 2022- WATERTOWN, Mass. and STOCKHOLM, Sweden, Dec. 01, 2021 (GLOBE NEWS